A German RA registry study reported herpes zoster incidence rates of 11.1 (95% CI 7.9-15.1) per 1000 patient-years for the monoclonal anti-TNF antibodies infliximab and adalimumab, and 8.9 (95% CI, 5.6-13.3) for etanercept, in comparison with 5.6 (95% CI, 3.6-8.3) for conventional DMARDs [120]. The gene discussed is TNF; the disease is rheumatoid arthritis.